Quanterix Corporation Restructuring Costs and Asset Impairment Charges
Quanterix Corporation (QTRX) reported Restructuring Costs and Asset Impairment Charges of $26.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-08-10
- Quanterix Corporation restructuring costs and asset impairment charges for the quarter ending 2026-06-30 was $26.93M, a 251.16% increase year-over-year.
- Quanterix Corporation restructuring costs and asset impairment charges for the quarter ending 2025-12-31 was $883.00K.
- Quanterix Corporation restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $7.17M.
- Quanterix Corporation restructuring costs and asset impairment charges for the quarter ending 2025-06-30 was $7.67M.
- Quanterix Corporation restructuring costs and asset impairment charges for fiscal 2025 was $15.73M.
- Quanterix Corporation restructuring costs and asset impairment charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Quanterix Corporation restructuring costs and asset impairment charges for fiscal 2023 was $1.33M, a 95.51% decline from fiscal 2022.
- Quanterix Corporation restructuring costs and asset impairment charges for fiscal 2022 was $29.56M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 3 month as first filed | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 9 month as first filed | Restructuring Costs and Asset Impairment Charges 12 month | Restructuring Costs and Asset Impairment Charges 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.93M 10-Q · filed 2026-08-10 | $46.77M 10-Q · filed 2026-08-10 | |||||
| 2025-12-31 | $883.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.06M derived: sum of 2 quarters · filed 2026-03-02 | $15.73M derived: sum of 3 quarters · filed 2026-08-10 | $15.73M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $7.17M 10-Q · filed 2025-11-10 | $14.84M derived: sum of 2 quarters · filed 2026-08-10 | $14.84M 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $7.67M 10-Q · filed 2026-08-10 | $7.67M 10-Q · filed 2026-08-10 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |||||
| 2023-12-31 | $1.36M 10-K/A · filed 2024-12-26 | $1.36M derived: sum of 2 quarters · filed 2024-12-26 | $1.36M derived: sum of 3 quarters · filed 2024-12-26 | $1.33M 10-K · filed 2026-03-02 | $1.54M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $0.00 10-K/A · filed 2024-12-26 | $0.00 derived: sum of 2 quarters · filed 2024-12-26 | -$33.00K 10-K/A · filed 2024-12-26 | $8.97M derived: sum of 4 quarters · filed 2024-12-26 | |||
| 2023-06-30 | $0.00 10-K/A · filed 2024-12-26 | -$33.00K 10-K/A · filed 2024-12-26 | $8.97M derived: sum of 3 quarters · filed 2024-12-26 | $29.32M derived: sum of 4 quarters · filed 2024-12-26 | |||
| 2023-03-31 | -$33.00K 10-K/A · filed 2024-12-26 | $8.97M derived: sum of 2 quarters · filed 2024-12-26 | $29.32M derived: sum of 3 quarters · filed 2024-12-26 | $29.52M derived: sum of 4 quarters · filed 2024-12-26 | |||
| 2022-12-31 | $9.01M 10-K/A · filed 2024-12-26 | $29.35M derived: sum of 2 quarters · filed 2024-12-26 | $29.56M derived: sum of 3 quarters · filed 2024-12-26 | $29.56M 10-K · filed 2025-03-17 | $29.35M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $20.34M 10-K/A · filed 2024-12-26 | $20.34M 10-Q · filed 2023-11-08 | $20.55M derived: sum of 2 quarters · filed 2024-12-26 | $20.55M 10-K/A · filed 2024-12-26 | $20.34M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $207.00K 10-K/A · filed 2024-12-26 | $207.00K 10-K/A · filed 2024-12-26 | |||||
| 2021-12-31 | $0.00 10-K/A · filed 2024-12-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |